Today: 9 June 2026
Why Intel Stock Hit a Record: Google AI Chip Report Puts Foundry Turnaround in Focus
30 April 2026
2 mins read

Why Intel Stock Hit a Record: Google AI Chip Report Puts Foundry Turnaround in Focus

SANTA CLARA, California, April 30, 2026, 04:02 (PDT)

  • Intel jumped to $94.75 early Thursday, a 12% move above its prior close. That surge followed last week’s earnings beat, which set off a sharp rally.
  • Driving the move: a report suggests Google is considering Intel’s EMIB advanced packaging tech for its upcoming TPU, the AI chip handling both training and inference.
  • Big numbers on both sides: Intel Foundry turned in $5.42 billion in revenue for the first quarter, yet ended up $2.44 billion in the red, according to a filing.

Intel stock surged to an all-time high Thursday morning, driven by word that Google may use the company’s advanced packaging tech in upcoming AI chips—a fresh vote of confidence in CEO Lip-Bu Tan’s overhaul strategy. Shares jumped 12.1% to hit $94.75, according to Barron’s, marking Intel’s biggest rally in years.

The shift is significant: Intel isn’t just being valued as a PC and server-chip company anymore. Now, investors are weighing if Intel Foundry—the expensive contract-manufacturing division—can actually attract external clients for AI chips and finally stop pulling down the company’s profit.

Apple is weighing Intel’s 18A-P process for upcoming M-series chips, TrendForce said Wednesday, citing Taiwan’s Commercial Times. Over at Google, the report adds, its TPU v8e might tap Intel’s EMIB—Embedded Multi-die Interconnect Bridge—a packaging technology that links separate chunks of silicon in a single chip. That’s a critical move as AI processors balloon in size and complexity.

Google rolled out its eighth-generation Tensor Processing Units last week, introducing TPU 8t for training and TPU 8i for inference—the step where AI models actually respond or act. The company made no mention of Intel as a supplier in that reveal.

Intel and Google already have a public partnership in place. Back on April 9, the two companies kicked off a multiyear deal involving Intel Xeon CPUs and custom infrastructure processing units—IPUs—meant for Google’s AI and cloud systems. Google’s Amin Vahdat described Intel as a “trusted partner for nearly two decades.” Intel

The new report comes just after Intel’s first-quarter revenue hit $13.6 billion—a 7% rise from last year—and the chipmaker is guiding for second-quarter revenue somewhere between $13.8 billion and $14.8 billion. CFO David Zinsner pointed to “unprecedented demand for silicon.” Adjusted EPS this quarter? Intel’s projecting 20 cents. Intel

Tan isn’t calling this demand uptick a passing blip. During last week’s analyst call, he pointed out that the CPU rebound linked to AI inference is “not just our wishful thinking.” Cloud providers, he said, are shifting heavier workloads to central processors, not just sticking with GPUs—the same graphics chips that put Nvidia in the lead during the early run-up of the AI surge. Reuters

Competition remains fierce. Last week, Reuters noted AMD and Arm gained alongside Intel as investors speculated that CPUs might reclaim a bigger piece of the AI pie through inference. Meanwhile, Nvidia stepped into CPU territory with its own new processor.

The rally may be outpacing the company’s fundamentals. Reuters noted Intel shares were changing hands at nearly 90 times forward earnings following last week’s jump—well above AMD’s 37 and Nvidia’s 22. Zinsner flagged that some of Intel’s first-quarter lift was tied to moving older or lower-spec inventory, a tailwind that might not show up again in Q2.

Intel, in its latest filing, spelled out risks: without sufficient committed demand for its next-gen Intel 14A manufacturing process, the company could hit pause—or even scrap—that node and future technologies, according to the document.

The foundry business keeps demanding cash. Intel has disclosed it repurchased Apollo’s 49% minority interest in the Ireland Fab 34 venture for roughly $14.2 billion this month, tapping cash, short-term investments, and a $6.5 billion term loan to fund the deal.

Investors are already betting on Intel, despite contracts not yet out in the open. Bob O’Donnell, who heads up TECHnalysis Research, told Reuters that if foundry business ramps up in 2027, that’s the real sign the “turnaround is complete.” Reuters

Stock Market Today

  • Soybean Prices Decline Amid Lower Export Shipments and Reduced Speculative Positions
    June 9, 2026, 9:21 AM EDT. Soybean prices fell between 2 and 5 ½ cents on Monday, with the national average cash price dropping to $10.58 3/4 per bushel. Export shipments for the week ending June 4 decreased by 21.2% from the previous week, totaling 398,186 MT, and are down 28.8% year-over-year. Key buyers included Egypt, China, and Mexico. Marketing year exports stand 20.3% lower compared to last year. Meanwhile, speculative traders reduced their net long positions in soybean futures and options by 33,502 contracts, signaling cautious market sentiment. Soymeal and soy oil futures also declined modestly. A private export sale of 264,000 MT was reported for the 2026/27 season, but overall market pressure weighs on prices going into the week.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
US Stock Market Today: Futures Rise Before GDP as Big Tech Earnings Split Wall Street
Previous Story

US Stock Market Today: Futures Rise Before GDP as Big Tech Earnings Split Wall Street

Amazon Stock Rises on AWS AI Growth — Why AMZN’s Cloud Beat Matters Now
Next Story

Amazon Stock Rises on AWS AI Growth — Why AMZN’s Cloud Beat Matters Now

Go toTop